CAS 71119-11-4: Bucindolol

Bucindolol (BMY 13105) is a novel and potent β1-adrenergic receptor blocker that mediates vasodilation and can be used to study chronic heart failure.

Applications Bucindolol is a high-affinity, competitive beta blocker used in the treatment of congestive heart failure and hypertension. References Hershberger, R., et al.: J. Cardiovasc. Pharm., 15, 959 (1990); Pollock, S., et al.: Am. J. Cardiol., 66, 603 (1990); Rotmensch, H., et al.: Am. J. Cardiol., 54, 353 (1984)

Bucindolol is a non-selective beta-blocker, which is a synthetic compound with affinity for beta-adrenergic receptors. These receptors are part of the autonomic nervous system and play a crucial role in cardiovascular function. Bucindolol acts by competitively antagonizing beta-1 and beta-2 adrenergic receptors, which results in decreased heart rate, myocardial contractility, and peripheral vascular resistance. Bucindolol is primarily investigated for its use in the management of chronic heart failure and certain types of cardiac arrhythmias. Its unique pharmacological profile also includes mild vasodilatory properties, attributed to partial agonist activity at beta-3 adrenergic receptors, which may contribute to its therapeutic effects. The drug's ability to influence both beta-1 and beta-2 receptors, along with its partial agonistic activity, makes it a subject of study for tailored therapeutic strategies, particularly in personalized medicine to address the genetic variability in adrenergic receptor gene polymorphisms. Research continues to explore its specific applications, optimal use cases, and long-term outcomes in diverse patient populations.